Clinical takeaway
Both therapies substantially lower LDL-C; treatment choice should reflect required intensity, dosing preference, adherence, access, and the maturity of outcomes evidence.
Mechanisms
- Inclisiran is an siRNA therapy that reduces hepatic PCSK9 production.
- Evolocumab is a monoclonal antibody that binds circulating PCSK9 and preserves LDL receptor recycling.
What separates them
- Inclisiran produces roughly 50% LDL-C reduction with maintenance dosing every six months after initiation.
- Evolocumab produces roughly 60% LDL-C reduction and has demonstrated cardiovascular event reduction in FOURIER.
- Inclisiran cardiovascular outcomes trials remain ongoing.
Practical selection
Consider additional LDL-C lowering needed, familial hypercholesterolemia, statin intolerance, injection frequency, adherence, patient preference, access, and the strength of available outcomes data.
References
- Ray KK, et al. N Engl J Med. 2020;382:1507-1519.
- Sabatine MS, et al. N Engl J Med. 2017;376:1713-1722.
Educational summary from Medeasy Review Issue 01. Verify recommendations against current guidelines, local approvals, product information, and the individual patient's circumstances.
